Clinical Trials

Raynaud's disease

Displaying 3 studies

UVA1 Phototherapy in Patients with Scleroderma-Related Raynaud’s Phenomenon Jacksonville, FL

The purpose of this study is to to evaluate patients undergoing the FDA-approved UVA1 phototherapy for systemic sclerosis pre, post, and during treatment for changes in their Raynaud’s phenomenon (RP) burden, digital ulcerations, and piecemeal necrosis.
A Study to Evaluate Intravenous Iloprost in Subjects with Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis No Locations

The purpose of this study is to evaluate the safety and effieativeness of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.
A Study to Evaluate Intravenous Iloprost in Subjects with Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis Rochester, MN

The purpose of this study is to evaluate the safety and effectiveness of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with systemic sclerosis.